# Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

> **NCT05964647** · PHASE1 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LSD (150 µg) + ketanserin (40 mg)
- **DRUG:** LSD (150 µg) + olanzapine (10 mg)
- **DRUG:** LSD (150 µg) + lorazepam (2 mg)
- **DRUG:** LSD (150 µg) + placebo
- **DRUG:** Placebo + placebo

## Key facts

- **NCT ID:** NCT05964647
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964647, "Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05964647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*